Related Research Articles
Estradiol benzoate (EB), sold under the brand name Progynon-B among others, is an estrogen medication which is used in hormone therapy for menopausal symptoms and low estrogen levels in women, in hormone therapy for transgender women, and in the treatment of gynecological disorders. It is also used in the treatment of prostate cancer in men. Estradiol benzoate is used in veterinary medicine as well. When used clinically, the medication is given by injection into muscle usually two to three times per week.
Estradiol enantate, also spelled estradiol enanthate and sold under the brand names Perlutal and Topasel among others, is an estrogen medication which is used in hormonal birth control for women. It is formulated in combination with dihydroxyprogesterone acetophenide, a progestin, and is used specifically as a combined injectable contraceptive. Estradiol enantate is not available for medical use alone. The medication, in combination with DHPA, is given by injection into muscle once a month.
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. It has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations. OHPH is given by injection into muscle at regular intervals.
Estradiol hexahydrobenzoate (EHHB), sold under a number of brand names including Benzo-Ginoestril A.P., BenzoGynoestryl Retard, Ginestryl-15-Depot, Menodin, and Tardoginestryl, is an estrogen medication which was previously used for indications such as menopausal hormone therapy and gynecological disorders. EHHB is given by injection into muscle at regular intervals, for instance once every few weeks.
Estradiol dienanthate (EDE), sold under the brand names Climacteron among others, is a long-acting estrogen medication which was previously used in menopausal hormone therapy for women and to suppress lactation in women. It was formulated in combination with estradiol benzoate (EB), a short-acting estrogen, and testosterone enanthate benzilic acid hydrazone (TEBH), a long-acting androgen/anabolic steroid. EDE has not been made available for medical use alone. The medication, in combination with EB and TEBH, was given by injection into muscle once or at regular intervals, for instance once every 6 weeks.
Estradiol benzoate/progesterone (EB/P4), sold under the brand names Duogynon and Sistocyclin among others, is a combination medication of estradiol benzoate (EB), an estrogen, and progesterone (P4), a progestogen. It has been formulated both as short-acting oil solutions and long-acting microcrystalline aqueous suspensions and is given by injection into muscle either once or continuously at regular intervals.
Estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone (EB/EDE/TEBH), sold under the brand names Climacteron, Lactimex, Lactostat, and Amenose, is an injectable combination medication of estradiol benzoate (EB), an estrogen, estradiol dienanthate (EDE), an estrogen, and testosterone enanthate benzilic acid hydrazone (TEBH), an androgen/anabolic steroid, which is used in menopausal hormone therapy for peri- and postmenopausal women and to suppress lactation in postpartum women. Clinical studies have assessed this formulation.
Estradiol cypionate/testosterone cypionate (EC/TC), sold under the brand names Depo-Testadiol and Femovirin among others, is an injectable combination medication of estradiol cypionate (EC), an estrogen, and testosterone cypionate (TC), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. It is specifically indicated for the treatment of moderate-to-severe vasomotor symptoms, but can also be used for other estrogen indications in women. The medication has also been used to suppress lactation in postpartum women.
Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate (EB/EPP/TP/TPP/TiC), sold under the brand names Estandron Prolongatum, Lynandron Prolongatum, and Mixogen, was an injectable combination medication of the estrogens estradiol benzoate (EB) and estradiol phenylpropionate (EPP) and the androgens/anabolic steroids testosterone propionate (TP), testosterone phenylpropionate (TPP), and testosterone isocaproate (TiC) which was used in menopausal hormone therapy for women. It was also used to suppress lactation in postpartum women.
Estradiol cypionate/testosterone enanthate (EC/TE), sold under the brand name Supligol, is an injectable combination medication of estradiol cypionate (EC), an estrogen, and testosterone enanthate (TE), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women, to treat prostatic hypertrophy in men, to treat osteoporosis, and to suppress lactation in women, among other uses. It contains 4 mg EC and 80 mg TE in oil solution in each ampoule and is administered by intramuscular injection once every 3 to 6 weeks for hormone therapy in women. The medication was marketed by 1976 and remains available today in Paraguay.
Estradiol cypionate/hydroxyprogesterone caproate (EC/OHPC), sold under the brand name Sinbios, is a combination medication of estradiol cypionate (EC), an estrogen, and hydroxyprogesterone caproate (OHPC), a progestin, which was reportedly used as a combined injectable contraceptive in women in the early 1970s. It contained 5 mg EC and 250 mg OHPC in oil solution, was provided in the form of 1 mL ampoules, and was administered by intramuscular injection at regular intervals. The medication was manufactured by the pharmaceutical company Mavi in Mexico.
Estradiol benzoate/estradiol valerate/hydroxyprogesterone caproate (EB/EV/OHPC), sold under the brand name Sin-Ol, is a combination medication of estradiol benzoate (EB), an estrogen, estradiol valerate (EV), an estrogen, and hydroxyprogesterone caproate (OHPC), a progestin, which was reportedly used as a combined injectable contraceptive in women in the early 1970s. It contained 1 mg EB, 10 mg EV, and 250 mg OHPC in oil solution, was provided in the form of 3 mL ampoules, and was administered by intramuscular injection at regular intervals. The medication was manufactured by the pharmaceutical company Reuffer in Mexico.
Estradiol benzoate/estradiol valerate/norethisterone acetate/testosterone enanthate (EB/EV/NETA/TE), sold under the brand name Ablacton, is an injectable combination medication of estradiol benzoate (EB), an estrogen, estradiol valerate (EV), an estrogen, norethisterone acetate (NETA), a progestin, and testosterone enanthate (TE), an androgen/anabolic steroid, which has been used to suppress lactation in women. It contains 5 mg EB, 8 mg EV, 20 mg NETA, and 180 mg TE in oil solution and is provided in the form of ampoules. It is given as a single intramuscular injection following childbirth. The medication was manufactured by Schering and was previously marketed in Italy and Spain, but is no longer available.
Progesterone/hydroxyprogesterone heptanoate/α-tocopherol palmitate (P4/OHPH/VE), sold under the brand name Tocogestan, is a combination medication of progesterone (P4), a short-acting progestogen, hydroxyprogesterone heptanoate (OHPH), a long-acting progestogen, and α-tocopherol palmitate, a prodrug of α-tocopherol and form of vitamin E, which was previously used in France to support pregnancy in women but is no longer available. It contained 50 mg P4, 200 mg OHPH, and 250 mg in 2 mL oil solution, was provided in the form of 2 mL ampoules, and was administered by intramuscular injection.
Estrone/progesterone/testosterone (E1/P4/T), sold under the brand name Tristeron or Tristerone, is an injectable combination medication of estrone (E1), an estrogen, progesterone (P4), a progestogen, and testosterone (T), an androgen/anabolic steroid, which was used in the treatment of functional uterine bleeding in women. It contained 6 mg estrone, 50 mg progesterone, and 25 mg testosterone in microcrystalline aqueous suspension and was administered by intramuscular injection. The medication was manufactured by Wyeth and was marketed by 1951. It is no longer available.
Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate (EDBu/OHPH/TCa), sold under the brand name Triormon Depositum, is an injectable combination medication of estradiol dibutyrate (EDBu), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone caproate (TCa), an androgen/anabolic steroid, which was used in the treatment of menopausal symptoms in women. It contained 3 mg EDBu, 30 mg OHPH, and 50 mg TCa in oil solution and was administered by intramuscular injection. The medication was developed by 1957. It is no longer available.
Estradiol hexahydrobenzoate/hydroxyprogesterone caproate/testosterone hexahydrobenzoate (EHHB/OHPC/THHB), sold under the brand name Trinestril AP, is an injectable combination medication of estradiol hexahydrobenzoate (EHHB), an estrogen, hydroxyprogesterone caproate (OHPC), a progestogen, and testosterone hexahydrobenzoate (THHB), an androgen/anabolic steroid. It contained 3 mg EHHB, 75 mg OHPC, and 100 mg THHB and was administered by intramuscular injection once per month. The medication was marketed by 1957.
Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate (EPC/OHPH/NU), tentative brand name Trophobolene or Trophoboline, is an injectable combination medication of estrapronicate, an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and nandrolone undecanoate (NU), an androgen/anabolic steroid, which was never marketed. It contained 1.3 mg EPC, 80 mg OHPH, and 50 mg NU in oil solution and was administered by intramuscular injection. The medication was developed by Théramex in the mid-to-late 1960s. It was studied for use for a variety of indications, including treatment of coronary insufficiency, growth deficiency, and osteoporosis, as well as hormonal disorders in gonadotropin deficiency.
Estradiol benzoate/progesterone/methandriol dipropionate (EB/P4/MADP), sold under the brand name Progestandron (Organon), is an injectable combination medication of estradiol benzoate (EB), an estrogen, progesterone (P4), a progestogen, and methandriol dipropionate (MADP), an androgen/anabolic steroid. It contained 3 mg EB, 20 mg P4, and 50 mg MADP, was provided in the form of ampoules, and was administered by intramuscular injection. The medication was marketed by 1957. It is no longer available.
Estradiol benzoate/progesterone/testosterone propionate (EB/P4/TP), sold under the brand names Lukestra, Steratrin, Trihormonal, and Trinestryl, is an injectable combination medication of estradiol benzoate (EB), an estrogen, progesterone (P4), a progestogen, and testosterone propionate (TP), an androgen/anabolic steroid. It contained 1 to 3 mg EB, 20 to 25 mg P4, and 25 mg TP, was provided in the form of ampoules, and was administered by intramuscular injection. The medication was introduced by 1949 and was marketed in the United States, the United Kingdom, and Germany among other places. It is no longer available.
References
- 1 2 Herschberg AD (October 1960). "[The menopause and the treatment of its disorders by a long-acting multihormone complex: trioestrine lente]". Gazette Médicale de France (in French). 67: 1987–1996. PMID 13713782.
- 1 2 Krówczyński L (1987). Extended Release Dosage Forms. CRC Press. p. 13. ISBN 978-0-8493-4307-0.
Hydroxyprogesterone heptanoate + testosterone cyclohexylpropionate + oestradiol undecanoate. Trioestrine-RetardR (Theramex). Oily solution for injection.
- 1 2 Kleemann A, Engel J (2001). Pharmaceutical substances: syntheses, patents, applications. Thieme. p. 1998. ISBN 978-3-13-558404-1.
- ↑ Bordier, Philippe (1963). "Cure of fifteen osteoporosis cases by a delayed effect of hormonal association". Semaine des Hopitaux. 39 (2): 81–4. ISSN 0037-1777.
The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.
- ↑ France (1964). Journal officiel de la République française.
Spécialité dénommée Trioestrine retard Theramex, soluté injectable I. M. : [...] Composition : heptylate d'hydroxy-17 alpha-progestérone, 10 g ; cyclohexyl propionate de testostérone, 10 g ; di-undécylate d'œstradiol, 0,5 g ; excipient Q. S. P. 100 ml (en boîtes de 2 ampoules de 1 ml).
- ↑ France (March 1953). Journal officiel de la République française. pp. 2564–.
- ↑ "Home". micromedexsolutions.com.
- ↑ "Trioestrine". Drugs.com.[ permanent dead link ]
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |